Alignment of Physician-Stated vs Clinically Derived Reference Fibrosis Score in Patients with Non-Alcoholic Steatohepatitis: A Real-World European Survey

Objective Stratifying disease severity in patients with non-alcoholic steatohepatitis (NASH) is essential for appropriate treatment and long-term management. Liver biopsy is the reference standard for fibrosis severity in NASH, but less invasive methods are used, eg, Fibrosis-4 Index (FIB-4) and vibration-controlled transient elastography (VCTE), for which reference thresholds for no/early fibrosis and advanced fibrosis are available. We compared subjective physician assessment of NASH fibrosis versus reference thresholds to understand classification in a real-world setting. Methods Data were drawn from Adelphi Real World NASH Disease Specific ProgrammeTM conducted in France, Germany, Italy, Spain and UK in 2018. Physicians (diabetologists, gastroenterologists, hepatologists) completed questionnaires for five consecutive NASH patients presenting for routine care. Physician-stated fibrosis score (PSFS) based on available information was compared with clinically defined reference fibrosis stage (CRFS) determined retrospectively using VCTE and FIB-4 data and eight reference thresholds. Results One thousand two hundred and eleven patients had VCTE (n = 1115) and/or FIB-4 (n = 524). Depending on thresholds, physicians underestimated severity in 16–33% (FIB-4) and 27–50% of patients (VCTE). Using VCTE ≥12.2, diabetologists, gastroenterologists and hepatologists underestimated disease severity in 35%, 32%, and 27% of patients, respectively, and overestimated fibrosis in 3%, 4%, and 9%, respectively (p = 0.0083 across specialties). Hepatologists and gastroenterologists had higher liver biopsy rates than diabetologists (52%, 56%, 47%, respectively). Conclusion PSFS did not consistently align with CRFS in this NASH real-world setting. Underestimation was more common than overestimation, potentially leading to undertreatment of patients with advanced fibrosis. More guidance on interpreting test results when classifying fibrosis is needed, thereby improving management of NASH.

[1]  V. Wong,et al.  Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis , 2021, Gut.

[2]  L. N. Valenti,et al.  Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. , 2021, Journal of hepatology.

[3]  A. Nunes,et al.  Using RWE research to extend clinical trials in diabetes: An example with implications for the future , 2020, Diabetes, obesity & metabolism.

[4]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[5]  L. Adams,et al.  Lifestyle modification in NAFLD/NASH: Facts and figures , 2019, JHEP reports.

[6]  Robert P. Myers,et al.  Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials , 2019, Hepatology.

[7]  P. Tandon,et al.  Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care , 2019, Hepatology communications.

[8]  R. Perry,et al.  A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH) , 2019, Advances in Therapy.

[9]  M. Allison,et al.  Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[10]  B. Neuschwander‐Tetri,et al.  Vibration‐Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  N. Sattar,et al.  Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease , 2018, BMC Medicine.

[12]  G. Pera,et al.  High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population‐Based Study , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  A. Camm,et al.  Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants , 2018, Open Heart.

[14]  S. Neubauer,et al.  Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI , 2018 .

[15]  N. Chalasani,et al.  Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. , 2018, Journal of hepatology.

[16]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[17]  M. Allison,et al.  Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey , 2017, Frontline Gastroenterology.

[18]  J. Piercy,et al.  Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015 , 2016, Diabetes, metabolic syndrome and obesity : targets and therapy.

[19]  M. Allison,et al.  Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis , 2016, The American Journal of Gastroenterology.

[20]  Julien Vergniol,et al.  Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[21]  Moon‐gyu Lee,et al.  What we need to know when performing and interpreting US elastography , 2016, Clinical and molecular hepatology.

[22]  J. Piercy,et al.  Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme , 2016, BMJ Open.

[23]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[24]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[25]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  Yoshito Itoh,et al.  Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. , 2014, World journal of gastroenterology.

[27]  Fabio Nascimbeni,et al.  From NAFLD in clinical practice to answers from guidelines. , 2013, Journal of hepatology.

[28]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[29]  A. Sanyal,et al.  Nonalcoholic fatty liver disease: Definitions, risk factors, and workup , 2012, Clinical liver disease.

[30]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[31]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  J. Piercy,et al.  Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand , 2008, Current medical research and opinion.

[33]  Marcus D. Ruopp,et al.  Youden Index and Optimal Cut‐Point Estimated from Observations Affected by a Lower Limit of Detection , 2008, Biometrical journal. Biometrische Zeitschrift.

[34]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[35]  K. Lundbaek,et al.  European Association for the study of diabetes , 1969, Diabetologia.

[36]  Is Liver Biopsy a Gold or an Old Standard in NAFL and NASH? , 2020 .

[37]  V. Wong,et al.  Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease , 2020 .

[38]  L. Henry,et al.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.

[39]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.